{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:35Z","timestamp":1790965115266,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T00:00:00Z","timestamp":1349827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Neuromyelitis optica (NMO) is caused by binding of pathogenic autoantibodies (NMO\u2010immunoglobulin G [IgG]) to aquaporin\u20104 (AQP4) on astrocytes, which initiates complement\u2010dependent cytotoxicity (CDC) and inflammation. We recently introduced mutated antibody (aquaporumab) and small\u2010molecule blocker strategies for therapy of NMO, based on prevention of NMO\u2010IgG binding to AQP4. Here, we investigated an alternative strategy involving neutralization of NMO\u2010IgG effector function by selective IgG heavy\u2010chain deglycosylation with bacteria\u2010derived endoglycosidase S (EndoS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Cytotoxicity and NMO pathology were measured in cell and spinal cord slice cultures, and in mice exposed to control or EndoS\u2010treated NMO\u2010IgG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>EndoS treatment of NMO patient serum reduced by &gt;95% CDC and antibody\u2010dependent cell\u2010mediated cytotoxicity, without impairment of NMO\u2010IgG binding to AQP4. Cytotoxicity was also prevented by addition of EndoS after NMO\u2010IgG binding to AQP4. The EndoS\u2010treated, nonpathogenic NMO\u2010IgG competitively displaced pathogenic NMO\u2010IgG bound to AQP4, and prevented NMO pathology in spinal cord slice culture and mouse models of NMO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation:<\/jats:title>\n                    <jats:p>EndoS deglycosylation converts pathogenic NMO\u2010IgG autoantibodies into therapeutic blocking antibodies. EndoS treatment of blood may be beneficial in NMO, and may be accomplished, for example, by therapeutic apheresis using surface\u2010immobilized EndoS. ANN NEUROL 2013<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ana.23741","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T04:17:35Z","timestamp":1346127455000},"page":"77-85","source":"Crossref","is-referenced-by-count":87,"title":["Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti\u2013aquaporin\u20104 immunoglobulin G into therapeutic antibody"],"prefix":"10.1002","volume":"73","author":[{"given":"Lukmanee","family":"Tradtrantip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ratelade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0764"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.72"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/72256"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70133-3"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611398939"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-008-0066-2"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22657"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-201608"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.1998.tb01188.x","article-title":"IgG\u2010Fc mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation","volume":"163","author":"Jefferis R","journal-title":"Immunol Rev"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001413"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.12.3046"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737581"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0808248105"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009090984"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06839.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1298"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.227298"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21802"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.344325"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22551"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp309"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22686"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0986-4"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.23741","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.23741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:06:03Z","timestamp":1697511963000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.23741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/ana.23741"],"URL":"https:\/\/doi.org\/10.1002\/ana.23741","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717957527.793461931","asserted-by":"object"}]},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,10]]}}}